# A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

> **NCT07274813** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 254 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors
- NSCLC

## Interventions

- **DRUG:** HLX37

## Key facts

- **NCT ID:** NCT07274813
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2027-03-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07274813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07274813, "A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07274813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*